Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2857–2880 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Cushing Syndrome
Interventions: Relacorilant, Placebo; Drug · Other
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Los Angeles, California • Torrance, California + 26 more

Conditions: Healthy
Interventions: PLX5622, Placebo; Drug
Lead sponsor: Plexxikon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Walking Impairment, Multiple Sclerosis
Interventions: ADS-5102, 137 mg, ADS-5102, 274 mg, Placebo; Drug · Other
Lead sponsor: Adamas Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 78
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 73 more

Conditions: Bipolar Disorder
Interventions: Valacyclovir, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, JNJ 28431754 300 mg/placebo, JNJ 28431754 100 mg/placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Chula Vista, California • San Antonio, Texas

Conditions: Cerebral Cavernous Malformations
Interventions: Propranolol, DNA and RNA Analysis; Drug · Genetic
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy
Interventions: TD-0714, Placebo Comparator; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Colonic Cancer
Interventions: Aquamin®, Calcium Carbonate, Placebo; Drug
Lead sponsor: James Varani; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Heart Failure With Reduced Ejection Fraction, HIV Infections
Interventions: Heart failure polypill, Control Rx; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatitis C
Interventions: VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more

Conditions: Osteoarthritis, Knee
Interventions: Intracapsular Injection, Periarticular Injection; Procedure
Lead sponsor: Broward Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Rheumatoid Arthritis
Interventions: Golimumab, Methotrexate, Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 20
States / cities: Peoria, Arizona • Aventura, Florida • Orlando, Florida + 17 more

Conditions: Hepatitis C
Interventions: TMC435, Ribavirin (R), PegIFNα-2a (P), Placebo; Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 12
States / cities: Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 9 more

Conditions: Femoro Acetabular Impingement
Interventions: LoopLoc Arm, Control Arm; Device
Lead sponsor: American Hip Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Des Plaines, Illinois

Conditions: Non-Cystic Acne
Interventions: VitaMedica® Clear Skin Formula capsules, Placebo Capsules; Dietary Supplement · Other
Lead sponsor: Ablon Skin Institute Research Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Manhattan Beach, California

Conditions: Healthy Participants
Interventions: TAK-418, TAK-418 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteers
Interventions: Placebo Comparator: Cohort 1 Placebo, 52364 3 mg, Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo, 52364 10 mg, 52364 30 mg, 52364 100 mg, 52364 1 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cocaine Dependence
Interventions: Clavulanic Acid Only Product, Placebo; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Charleston, South Carolina

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 61
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more

Conditions: Nonrestorative Sleep
Interventions: PD 0200390, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 52
States / cities: Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 45 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GLWL-01, Part A, Placebo, Part A, GLWL-01, Part B, Placebo, Part B, GLWL-01, Part C, Placebo, Part C; Drug
Lead sponsor: GLWL Research Inc.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Tempe, Arizona • Chula Vista, California • Miami, Florida + 1 more

Conditions: Migraine, Acute Treatment of Migraine
Interventions: Rimegepant, Placebo, Sumatriptan; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,026 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 41
States / cities: Scottsdale, Arizona • Tempe, Arizona • San Francisco, California + 35 more

Conditions: Alzheimer Disease
Interventions: BMS-708163, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 20 Years to 45 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Glendale, California

Conditions: Infections, Bacterial
Interventions: GSK1322322 Initial fit for purpose tablets, GSK1322322 over granulated tablets, GSK1322322 intended commercial tablets, Placebo tablets, 13C-GSK1322322 stable isotope powder, GSK1322322 for injection, Placebo injection; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

Research Study of Bipolar Mood Symptoms and Cognitive Problems

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation

Single Ascending Dose Study of TD-0714 in Healthy Subjects

Aquamin and Prevention of Colon Cancer

Heart Failure Polypill at a Safety Net Hospital

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

Postoperative Pain Control Results Using Periarticular Versus Intra-capsular Injection of Bupivacaine Liposome Injectable Suspension in Total Knee Arthroplasty

A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

Knotless Implants As an Alternative for Capsular Closure in Primary Hip Arthroscopy: a Prospective, Multi-Center Study

A Study to Evaluate the Efficacy and Safety of Clear Skin Formula on Mitigating Mild to Moderate Non-cystic Acne

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

First Safety Study in Humans of a Single Dose of CPG 52364

Clavulanic Acid for the Treatment of Cocaine Use Disorder

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

Multiple Dose Japanese Bridging Study

A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects